Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab in addition to radiation therapy for glioblastoma – first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation	Glioma	Neurological Cancer	2018	View \| Download
Nivolumab in addition to temozolomide and radiotherapy for MGMT-methylated glioblastoma in newly diagnosed adults - first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation , Temozolomide (Temodar; Temodal; SCH 52365)	Glioma	Neurological Cancer	2019	View \| Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation	Melphalan hydrochloride (Cydex; CDX-353; Phelinun)	Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer	Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer	2021	View \| Download
Selumetinib for treating symptomatic, inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in adults	Selumetinib (AZD6244; ARRY-142886)	Plexiform neurofibromas	Neurological Cancer , Neurology	2023	View \| Download
Toca 511 and Toca FC for Recurrent High Grade Glioma	Toca-511 (vocimagene amiretrorepvec) , Toca-FC (flucytosine)	Glioma	Neurological Cancer	2018	View \| Download
Vorasidenib for treating residual or recurrent grade 2 glioma	Vorasidenib	Glioma	Neurological Cancer	2023	View \| Download